ENTRY       D10526            Mixture   Drug
NAME        Trifluridine and tipiracil hydrochloride;
            Lonsurf (TN)
PRODUCT     LONSURF (Taiho Pharmaceutical)
COMPONENT   Trifluridine [DR:D00391], Tipiracil hydrochloride [DR:D10467]
REMARK      Therapeutic category: 4299
            ATC code: L01BC59
            Product: D10526<JP/US>
EFFICACY    Antineoplastic
  DISEASE   Colorectal cancer [DS:H00020]
            Gastric cancer [DS:H00018]
INTERACTION  
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L01 ANTINEOPLASTIC AGENTS
               L01B ANTIMETABOLITES
                L01BC Pyrimidine analogues
                 L01BC59 Trifluridine, combinations
                  D10526  Trifluridine and tipiracil hydrochloride &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Antineoplastics
              Antineoplastics, Other
               Trifluridine/ Tipiracil
                D10526  Trifluridine and tipiracil hydrochloride
            Therapeutic category of drugs in Japan [BR:br08301]
             4  Agents affecting cellular function
              42  Antineoplastics
               429  Miscellaneous
                4299  Others
                 D10526  Trifluridine and tipiracil hydrochloride
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D10526
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D10526
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D10526
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D10526
DBLINKS     PubChem: 254741488
            ChEBI: 90876
///
